Viking Therapeutics' shares plunged after mixed phase 2 results for a GLP-1 candidate. However, the data wasn't nearly as bad ...

The investigational GLP-1 receptor agonist MET-097i, which may be able to be dosed just once a month, yielded weight loss of ...

Pfizer's purchase of Metsera marks a significant step in enhancing its pipeline of GLP-1 medications. With Metsera’s investigational drugs, such as MET-097i and MET-233i, Pfizer is positioning itself ...

MET-097i’s mid-stage performance “bodes well” for Pfizer’s proposed buyout of Metsera, according to BMO Capital Markets, a ...

Morgan Stanley analyst Thibault Boutherin pointed to slowing momentum in U.S. prescriptions for Novo's flagship GLP-1 drugs, ...

LifeMD (LFMD) stock is in focus as the firm expands its telehealth collaboration with Novo Nordisk to offer the pharma ...

President Donald Trump and Pfizer's CEO today announced "TrumpRX" and lower drug prices. But what does Pfizer sell? Here's ...

Discover why MDGL's Rezdiffra leads in MASH therapy with rapid US and EU expansion. Learn about growth potential and risks.

Ozempic is the trade name for semaglutide, a once-weekly injectable medicine that belongs to the class called GLP-1 receptor ...

Hanmi Pharmaceutical has applied for Phase 1 clinical trials to commercialize a "novel obesity drug" that, for the first time ...

Weight loss jabs are not only helping people lose the weight-thousands of users say their hair is falling out too.